Efficacy News and Research

RSS

D-Pharm announces promising results with drug candidates in models of HAT and malaria

D-Pharm Ltd., announced today on-line publication of promising results with its drug candidates, DP-460 and DP-b99, in models of human African trypanosomiasis (HAT) and malaria.

20 Aug 2013

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Advaxis, Inc., (OTCQB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer.

17 Aug 2013

Experts research on potential role of e-cigarettes in smoking cessation

With the third and largest of the U.S. tobacco companies planning an e-cigarette product launch this fall, this next frontier for "Big Tobacco" provides renewed presence in a declining marketplace. It's also a potential gateway to new smokers, particularly among teens and in emerging/foreign markets, according to behavioral scientists at The University of Texas MD Anderson Cancer Center.

17 Aug 2013

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.

17 Aug 2013

Study: Type 2 diabetic patients treated with DPP-4 linagliptin experience reductions in blood glucose levels

Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.

17 Aug 2013

Chemo before radiotherapy improves efficacy of treatment in testicular cancer patients with low side effects

Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk of long-term side-effects, a new study reports.

17 Aug 2013

More research needed to understand potential role of e-cigarettes in smoking cessation, say experts

With the third and largest of the U.S. tobacco companies planning an e-cigarette product launch this fall, this next frontier for “Big Tobacco” provides renewed presence in a declining marketplace. It’s also a potential gateway to new smokers, particularly among teens and in emerging/foreign markets, according to behavioral scientists at The University of Texas MD Anderson Cancer Center.

16 Aug 2013

Surgeons evaluate combined surgery technique to remove cancerous tumors from rectum

Surgeons at the University of California, San Diego School of Medicine are evaluating a new, combined surgery technique to remove cancerous tumors from the rectum. The hybrid technique uses the body's natural opening to remove malignancies and diseased tissue while also performing reconstruction.

16 Aug 2013

Intervention delivered through mobile phones to HIV/AIDS-positive smokers increased cessation rates

A smoking-cessation intervention delivered through mobile phones to HIV/AIDS-positive smokers increased cessation rates compared to standard care, according to research published online in Clinical Infectious Diseases.

16 Aug 2013

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

16 Aug 2013

Animal model of HIV sexual transmission

Infection by human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a debilitating disorder in which progressive weakening of the immune system makes affected individuals more susceptible to potentially life-threatening infections and chronic diseases. Despite advances in the treatment and management of AIDS, there is no cure, and HIV infection remains a major global health problem.

16 Aug 2013

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim today announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete.

15 Aug 2013

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Oraya Therapeutics, Inc. announced today that the Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy.

14 Aug 2013

Women diagnosed for menopause after breast cancer may vary with type of doctors

Hormonal treatment for breast cancer causes menopause in over 80% of women in the first year of therapy, but now new research, published in the peer-reviewed journal Climacteric, has found that how these women are diagnosed and treated for menopausal symptoms can vary substantially according to which type of doctor a woman sees.

13 Aug 2013

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

13 Aug 2013

Harvard University receives grant to use organs-on-chips device to test human response to radiation

A team at the Wyss Institute for Biologically Inspired Engineering at Harvard University has received a $5.6 million grant award from the United States Food and Drug Administration (FDA) to use its Organs-on-Chips technology for a novel application of keen interest to national security and health officials: to test human physiological responses to radiation, and to evaluate drugs designed to counter those effects.

13 Aug 2013

Study provides efficient strategy for prevention of rotavirus infection

For children and immune compromised adults in developing countries, diarrheal disease induced by rotavirus can be life threatening. Current rotaviral vaccines are highly effective in the Western world, but are not as effective in developing countries.

9 Aug 2013

One-third of patients with heart pumps develop infection at abdominal power connection site

Cardiac surgeons and cardiologists at the University of Maryland Heart Center are part of a multi-center clinical trial evaluating the efficacy of powering heart pumps through a skull-based connector behind the ear. Typically, these devices for patients with severe heart failure are energized through an electrical cord connected at an abdominal site, where potentially deadly infections can develop.

8 Aug 2013

AmpliPhi releases data on phage therapy for treatment of lung infections in Cystic Fibrosis patients

AmpliPhi BioSciences Corp. (OTC: APHB) ("AmpliPhi"), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment of Pseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held in Olympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients.

8 Aug 2013

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial.

8 Aug 2013

Efficacy News and Research

D-Pharm announces promising results with drug candidates in models of HAT and malaria

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Experts research on potential role of e-cigarettes in smoking cessation

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Study: Type 2 diabetic patients treated with DPP-4 linagliptin experience reductions in blood glucose levels

Chemo before radiotherapy improves efficacy of treatment in testicular cancer patients with low side effects

More research needed to understand potential role of e-cigarettes in smoking cessation, say experts

Surgeons evaluate combined surgery technique to remove cancerous tumors from rectum

Intervention delivered through mobile phones to HIV/AIDS-positive smokers increased cessation rates

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Animal model of HIV sexual transmission

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Women diagnosed for menopause after breast cancer may vary with type of doctors

FDA: New drug Tivicay approved to treat HIV-1 infection

Harvard University receives grant to use organs-on-chips device to test human response to radiation

Study provides efficient strategy for prevention of rotavirus infection

One-third of patients with heart pumps develop infection at abdominal power connection site

AmpliPhi releases data on phage therapy for treatment of lung infections in Cystic Fibrosis patients

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News